CANCER VACCINES MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-33850 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Cancer Vaccines Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL CANCER VACCINES MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL CANCER VACCINES MARKET
7.1 GLOBAL CANCER VACCINES MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL CANCER VACCINES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL CANCER VACCINES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL CANCER VACCINES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL CANCER VACCINES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL CANCER VACCINES MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL CANCER VACCINES MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA CANCER VACCINES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA CANCER VACCINES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA CANCER VACCINES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA CANCER VACCINES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA CANCER VACCINES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA CANCER VACCINES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE CANCER VACCINES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE CANCER VACCINES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE CANCER VACCINES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE CANCER VACCINES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE CANCER VACCINES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE CANCER VACCINES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC CANCER VACCINES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC CANCER VACCINES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC CANCER VACCINES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC CANCER VACCINES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC CANCER VACCINES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC CANCER VACCINES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA CANCER VACCINES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA CANCER VACCINES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA CANCER VACCINES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA CANCER VACCINES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA CANCER VACCINES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA CANCER VACCINES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Advaxis Inc.
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Amgen Inc.
16.3 Dynavax Technologies Corporation
16.4 Generex Biotechnology Corporation
16.5 GlaxoSmithKline plc (GSK)
16.6 Immunocellular Therapeutics, Ltd
16.7 Merck & Co., Inc.
16.8 Sanpower Group Co. Ltd .(Dendereon Corporation)
16.9 UbiVac
16.10 Vaccinogen, Inc.
16.11 OSE Immunotherapeutics
16.12 Dendreon Pharmaceuticals LLC
16.13 Aduro BioTech Inc.
16.14 Astellas Pharma Inc.
16.15 R-BioPharma AG
16.16 AstraZeneca PLC
16.17 Bristol-Myers Squibb
16.18 Sanofi
16.19 Welland Medical Ltd
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By Technology  Dendritic Cells (DC) Cancer Vaccines
Recombinant Cancer Vaccines
Antigen/Adjuvant Cancer Vaccines
Viral Vector & DNA Cancer Vaccines
By Indication
Cervical Cancer
Prostate Cancer
Others
By Type
Preventive Cancer Vaccines
Therapeutic Cancer Vaccines
By End User
Pediatrics
Adults
Companies
Advaxis Inc.
Amgen Inc.
Dynavax Technologies Corporation
Generex Biotechnology Corporation
GlaxoSmithKline plc (GSK)
Immunocellular Therapeutics, Ltd
Merck & Co., Inc.
Sanpower Group Co. Ltd .(Dendereon Corporation)
UbiVac
Vaccinogen, Inc.
OSE Immunotherapeutics
Dendreon Pharmaceuticals LLC
Aduro BioTech Inc.
Astellas Pharma Inc.
R-BioPharma AG
AstraZeneca PLC
Bristol-Myers Squibb
Sanofi
Welland Medical Ltd
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.